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Abstract The Axin-dependent phosphorylation of L-catenin
catalysed by glycogen synthase kinase-3 (GSK3) is inhibited
during embryogenesis. This protects L-catenin against ubiquitin-
dependent proteolysis, leading to its accumulation in the nucleus,
where it controls the expression of genes important for
development. Frequently rearranged in advanced T-cell lympho-
mas 1 (FRAT1) is a mammalian homologue of a GSK3-binding
protein (GBP), which appears to play a key role in the correct
establishment of the dorsal-ventral axis in Xenopus laevis. Here,
we demonstrate that FRATtide (a peptide corresponding to
residues 188^226 of FRAT1) binds to GSK3 and prevents GSK3
from interacting with Axin. FRATtide also blocks the GSK3-
catalysed phosphorylation of Axin and L-catenin, suggesting a
potential mechanism by which GBP could trigger axis formation.
In contrast, FRATtide does not suppress GSK3 activity towards
other substrates, such as glycogen synthase and eIF2B, whose
phosphorylation is independent of Axin but dependent on a
‘priming’ phosphorylation. This may explain how the essential
cellular functions of GSK3 can continue, despite the suppression
of L-catenin phosphorylation.
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1. Introduction
Glycogen synthase kinase-3 (GSK3) is a serine/threonine-
speci¢c protein kinase that is thought to phosphorylate many
proteins in vivo and therefore to play key roles in the regu-
lation of a variety of cellular processes [1]. For example,
GSK3 lies in an insulin-stimulated, phosphatidylinositide
(PI) 3-kinase-dependent pathway that leads to the stimulation
of glycogen and protein synthesis in mammalian cells. In this
pathway, GSK3 is inhibited by phosphorylation at a speci¢c
serine residue catalysed by protein kinase B (PKB). This pre-
vents GSK3 from phosphorylating and inhibiting glycogen
synthase [2,3] and protein synthesis initiation factor eIF2B
[4], contributing to the insulin-induced stimulation of glyco-
gen and protein synthesis. The insulin-induced PI 3-kinase-
dependent inhibition of GSK3 also underlies the dephospho-
rylation of the microtubule-associated protein Tau in neurons
[5].
The inhibition of GSK3 is also critical for the speci¢cation
of cell fates during embryogenesis. For example, inhibition of
GSK3 is essential for the patterning of segments during early
embryogenesis in Drosophila and occurs in response to a sig-
nalling pathway initiated by the glycoprotein Wingless [6].
The inhibition of GSK3 in this situation is not mediated by
PKB and appears to involve the phosphorylation of a distinct
serine residue(s) [7]. A homologous pathway operates in Xen-
opus laevis ventral mesoderm development and anterior-pos-
terior neural patterning in which Wingless homologues
(termed Wnts) mediate the inhibition of GSK3 [8].
The inhibition of GSK3 during embryogenesis suppresses
its ability to phosphorylate L-catenin, protecting L-catenin
against ubiquitin-dependent proteolysis. This leads to the ac-
cumulation of L-catenin in the nucleus where it controls the
expression of genes important for development [9]. The
GSK3-catalysed phosphorylation of L-catenin depends on
the presence of Axin, a protein that forms a complex with
GSK3 and L-catenin [9^11]. Axin is also a substrate for
GSK3 and the Wnt-induced dephosphorylation of Axin
causes it to bind L-catenin with a reduced e⁄ciency [12].
Thus, Wnt signaling lowers Axin’s a⁄nity for L-catenin, dis-
engaging L-catenin from the degradation machinery.
In early X. laevis development, localised inhibition of GSK3
is required for correct establishment of the dorsal-ventral axis.
However, no Wnts that might mediate this process have yet
been identi¢ed, raising the possibility that a di¡erent mecha-
nism is involved. Recently, a novel GSK3-binding protein
(GBP) has been identi¢ed in Xenopus embryos [13] and zebra-
¢sh [14], which may function in vivo to stabilise L-catenin.
Injection of GBP antisense RNA prevents correct axis forma-
tion, while injection of GBP mRNA into the ventral region of
the embryo leads to the formation of a second axis and there-
fore produces a tadpole with two heads [13]. These observa-
tions are consistent with GBP functioning as an inhibitor of
GSK3 in vivo, but whether GBP can act in the absence of
Wnt signalling or whether it cooperates with as yet unidenti-
¢ed Wnts to achieve stabilisation of L-catenin is unclear.
Moreover, the e¡ects of GBP on GSK3 activity in vitro
have not yet been reported.
GBP exhibits limited homology with a previously identi¢ed
mammalian protein termed frequently rearranged in advanced
T-cell lymphomas 1 (FRAT1) [15], while another homologue,
FRAT2 (Fig. 1), mimics the e¡ect of GBP on secondary axis
formation [13]. FRAT1 is an oncogene upregulated during
infection with Moloney murine leukaemia virus and FRAT1
expression confers a selective advantage to tumour cells that
overexpress Myc and Pim1 [15]. The C-terminal half of GBP
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is su⁄cient to bind GSK3 and to mediate its e¡ects on axis
formation [13]. Here, we show that FRATtide, a 39 residue
peptide from the C-terminus of FRAT1, binds to GSK3 and
prevents the binding of Axin. FRATtide also blocks the
GSK3-catalysed phosphorylation of Axin and L-catenin, sug-
gesting a potential way in which GBP could control axis for-
mation. Interestingly, FRATtide does not inhibit GSK3 activ-
ity towards substrates whose phosphorylation is independent
of Axin and which possess a ‘priming’ phosphorylation. This
selectivity may allow for many essential cellular functions of
GSK3 to continue, despite the suppression of L-catenin phos-
phorylation.
2. Materials and methods
2.1. Materials
Glutathione-Sepharose and CNBr-activated Sepharose were pur-
chased from Pharmacia and nickel-nitrilotriacetate-agarose from Qia-
gen (West Sussex, UK). All other reagents were from Sigma (Poole,
UK) and E. Merck (Poole, UK).
2.2. Proteins
The peptide SQPETRTGDDDPHRLLQQLVLSGNLIKEAVRR-
LHSRRLQ (FRATtide, residues 188^226 of human FRAT1), the
phosphopeptide YRRAAVPPSPSLSRHSSPHQSpEDEEE (GS-1,
closely related to a sequence towards the C-terminus of glycogen
synthase and phosphorylated at the most C-terminal serine) and the
phosphopeptide RRAAEELDSRAGSpPQL (corresponding to two
arginines followed by residues 534^547 of the O subunit of eIF2B
and phosphorylated at the most C-terminal serine) were synthesised
by Dr. S. Bloomberg, University of Bristol, UK. The underlined res-
idues indicate sites phosphorylated by GSK3. The K and L isoforms of
GSK3 [16,17] and glycogen synthase [18,19] were puri¢ed from rabbit
skeletal muscle. A⁄nity-puri¢ed His-tagged human GSK3L, obtained
from Sf9 cells, was used in the Axin and L-catenin phosphorylation
experiments. Glutathione S-transferase (GST) fused in frame to resi-
dues 281^500 of human Axin in the vector pGEX-3X (Pharmacia)
was expressed in Escherichia coli. Bacteria were grown to the mid-
log phase, induced at 30‡C with isopropylthiogalactoside, lysed by
sonication in Triton X-100-containing bu¡er and puri¢ed by chroma-
tography on glutathione-Sepharose. After washing, the GST-
Axin[281^500] was eluted with bu¡er containing 10 mM glutathione.
Murine GST-L-catenin (a gift from Dr. A. Huber, Stanford Univer-
sity, CA, USA) and the 412 residue form of human Tau [20] were
expressed in E. coli and puri¢ed. A polyclonal anti-peptide antibody
that recognises GSK3K speci¢cally was raised in sheep [21] and a
monoclonal mouse antibody against the L isoform of GSK3 was pur-
chased from Transduction Laboratories (Lexington, KY, USA).
Horseradish peroxidase-linked secondary antibodies (sheep anti-
mouse IgG and rabbit anti-sheep IgG) were from the Scottish Anti-
body Production Unit (Carluke, UK) and Pierce (Chester, UK), re-
spectively.
2.3. Cell culture and transfection
Human embryonic kidney 293 cells were transfected as in [22] with
10 Wg of pEBG-2T vector DNA expressing GST or GST-FRATtide.
24 h later, the cells were lysed in 1 ml of 20 mM Tris-acetate, pH 7.5,
1 mM EGTA, 1 mM EDTA, 1% (w/v) Triton X-100, 1 mM sodium
orthovanadate, 50 mM sodium £uoride, 5 mM sodium pyrophos-
phate, 0.27 M sucrose, 1 WM microcystin-LR, 0.1% (v/v) L-mercap-
toethanol, 1 mM benzamidine, 4 Wg/ml leupeptin. Lysates were cen-
trifuged at 4‡C for 5 min at 13 000Ug and the supernatant used for
analysis.
2.4. Coupling of FRATtide to Sepharose
CNBr-activated Sepharose (1 ml settled volume) was coupled to
1 ml of 0.5 mM FRATtide in 0.1 M NaHCO3, pH 8.0, 0.5 M
NaCl according to the manufacturer’s protocol, except that 0.5 M
NaCl was included during coupling and initial washing steps. Finally,
the beads were washed four times with 50 mM Tris-HCl, pH 7.5,
0.1 mM EGTA, 0.1% (v/v) 2-mercaptoethanol, 0.03% (m/v) Brij 35
(bu¡er A) and stored as a 50% slurry in bu¡er A until use.
2.5. Phosphorylation of Tau with MAP kinase
Tau (4 WM) was phosphorylated to 2.5 mol/mol by incubation for
24 h at 30‡C in bu¡er A with or without 0.5 U/ml p42 MAP kinase,
10 mM magnesium acetate, 0.1 mM [Q-32P]ATP. One unit of MAP
kinase was that amount which catalysed the phosphorylation of
1 nmol myelin basic protein in 1 min [23].
2.6. Assay of GSK3
The assay (0.02 ml) was carried out in bu¡er A, containing GSK3
(2 mU), protein (2 WM) or peptide (20 WM) substrate, 10 mM mag-
nesium acetate and 0.1 mM [Q-32P]ATP. FRATtide was also present
where indicated. After 10 min at 30‡C, assays with protein substrates
were stopped by addition of 5 Wl of 10% (w/v) sodium dodecyl sulfate
(SDS), heated for 5 min at 95‡C and then electrophoresed on a 12%
(w/v) SDS-polyacrylamide gel. Gels were autoradiographed to detect
phosphorylated proteins and stained with Coomassie blue. Assays
with peptides were terminated by spotting 16 Wl of the reaction mix
on to P81 phosphocellulose paper followed by immersion in 75 mM
phosphoric acid. The P81 papers were washed and analysed by Cer-
enkov counting as described [24]. One unit of GSK3 was that amount
which catalysed the incorporation of 1 nmol of phosphate into pep-
tide GS-1 in 1 min. All assays were carried out at dilutions where
substrate phosphorylation was linear with respect to time.
2.7. Disruption of the GSK3-Axin complex by FRATtide
Glutathione-Sepharose was washed three times with 10 volumes of
ice-cold bu¡er A. 2 Wg of GST-Axin[281-500] in 50 Wl of bu¡er A was
then added to 10 Wl (settled volume) of the washed glutathione-Se-
pharose and the mixture was incubated for 30 min at 4‡C on a shak-
ing platform. The beads were brie£y centrifuged, the supernatant
removed and the beads then washed four times with 1 ml of bu¡er
A containing 150 mM NaCl to remove any unbound GST-Axin[281-
500]. GSK3 (50 ng) in 10 Wl of bu¡er A plus 1 mg/ml bovine serum
albumin (BSA) was incubated for 10 min at room temperature with
10 Wl of water or 0.2 mM FRATtide in water and then added to the
GST-Axin beads. After incubation for 1 h at 4‡C on a shaking plat-
form, the beads were centrifuged and the supernatant was removed
and denatured in SDS. The beads were washed twice in bu¡er A
containing 150 mM NaCl and then also denatured in SDS. The
SDS-denatured proteins were electrophoresed on 10% (w/v) SDS-pol-
yacrylamide gels, transferred to nitrocellulose and immunoblotted us-
ing the anti-GSK3K antibody (1 Wg/ml) or anti-GSK3L antibody
(500 ng/ml) using the ECL system (Amersham International, UK).
2.8. GSK3-catalysed phosphorylation of Axin and L-catenin
His-tagged human GSK3L was incubated with various concentra-
tions of FRATtide or water for 10 min at an ambient temperature in
0.01 ml of bu¡er A plus 1 mg/ml BSA. Assays (0.02 ml) were carried
out as described above in bu¡er A containing 0.1 mg/ml BSA, 25 mU
of GSK3L and 92 nM Axin and/or 1 Wg of GST-L-catenin as indicated
in the ¢gure legends.
3. Results and discussion
The C-terminal half of GBP, which is su⁄cient to bind
GSK3 and to mediate the e¡ects of GBP on axis formation
[13], contains only one region of about 30 residues that is
strikingly similar to its mammalian homologues FRAT1 [15]
and FRAT2 (Fig. 1). The importance of this region for the
function of GBP is indicated by the ¢nding that mutation of
two residues that lie within it (Lys-139 and Glu-140) abolishes
binding to GSK3 and axis-inducing activity [13]. We therefore
expressed a 39 residue peptide corresponding to residues 188^
226 of FRAT1 (FRATtide) as a GST fusion in 293 cells and,
after a⁄nity puri¢cation from the cell lysates on glutathione-
Sepharose, tested for the presence of GSK3 by immunoblot-
ting. These experiments demonstrated that GSK3K (Fig. 2A)
and GSK3L (data not shown) were complexed to GST-
FRATtide, but not to GST, and that the complex was stable
to washing in bu¡er containing 0.5 M NaCl (Fig. 2A). Im-
munoblotting of the supernatants showed that s 90% of the
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GSK3K and 80% of the GSK3L had been depleted from the
lysate by GST-FRATtide (data not shown). The a⁄nity of
FRATtide for GSK3 was also demonstrated by quantitative
binding of puri¢ed GSK3K (Fig. 2B) or GSK3L (Fig. 2C) to
FRATtide coupled to Sepharose. Minimal GSK3 was found
associated with Sepharose beads lacking bound FRATtide
(Fig. 2B,C).
FRATtide blocked the interaction of GSK3 with GST-
Axin[281-500] (Fig. 3), suggesting that the binding sites on
GSK3 for FRAT/GBP and Axin may overlap (despite the
lack of sequence similarity between them). FRATtide also
prevented the GSK3-catalysed phosphorylation of Axin[281-
500] (Fig. 4A). Since the GSK3-catalysed phosphorylation of
L-catenin requires the presence of Axin ([9^11] and see Fig.
4B), these ¢ndings implied that Axin-dependent phosphoryla-
tion of L-catenin should also be blocked by FRATtide. This
was indeed found to be the case (Fig. 4B).
These observations may be relevant to GBP’s ability to
promote axis formation. Thus, displacement of Axin from
GSK3 by GBP may mimic or facilitate the action of Wnts
by helping to suppress the GSK3-catalysed phosphorylation
of L-catenin. This would be expected to lead to stabilisation of
L-catenin [9^11] and hence to regulation of the expression of
genes essential for axis formation. In turn, the suppression of
Axin phosphorylation should promote its degradation [25]
and reduce its binding to L-catenin [12], thereby amplifying
the e¡ect of GBP to stabilise L-catenin.
In addition to its role in regulating embryogenesis, GSK3
participates in insulin signal transduction where its inhibition
by PKB underlies some of the important metabolic e¡ects of
this hormone, such as the activation of glycogen synthase and
eIF2B and dephosphorylation of Tau (Section 1). Indeed, the
peptide substrate used to assay GSK3 routinely (GS-1) is
closely related to the sequence surrounding the serine residues
on glycogen synthase that are phosphorylated by GSK3. In-
terestingly, FRATtide did not a¡ect the activity of GSK3
towards the peptide GS-1 (Fig. 5A, see also Fig. 2B,C) or
the glycogen synthase protein itself (Fig. 5C). Consistent
with these observations, the overexpression of GST-FRATtide
in 293 cells did not cause any activation (dephosphorylation)
of glycogen synthase, nor did it a¡ect the ability of insulin-like
Fig. 1. Amino acid sequences of Xenopus GBP, human FRAT1 and human FRAT2. Identities are shaded in black and similarities in grey. The
region near the C-terminus of FRAT1 that is strikingly conserved in GBP and FRAT2, termed FRATtide, is indicated.
Fig. 2. FRATtide forms a complex with GSK3. (A) Human embry-
onic kidney 293 cells expressing either GST or GST-FRATtide were
lysed and 0.5 mg of lysate protein was added to 10 Wl of gluta-
thione-Sepharose equilibrated in lysis bu¡er. After mixing for 90
min at 4‡C, the beads were washed four times with lysis bu¡er plus
the indicated concentrations of NaCl. Proteins attached to the beads
were denatured in SDS, electrophoresed on 10% SDS-polyacryl-
amide gels, transferred to nitrocellulose and immunoblotted using
anti-GSK3K antibody (1 Wg/ml). GST and GST-FRATtide were ex-
pressed to similar levels as judged by immunoblotting with anti-
GST antibodies (not shown). (B and C) GSK3K (B) or GSK3L (C),
both at 1 U/ml in bu¡er A plus 1 mg/ml BSA, were added to 10 Wl
(settled volume) of Sepharose-FRATtide (open bars) or Sepharose
alone (closed bars). After incubation with shaking for 1 h at 4‡C,
the suspension was centrifuged brie£y to pellet the beads and the
supernatant removed and placed on ice. The beads were washed
twice with bu¡er A plus 0.15 M NaCl and excess liquid was re-
moved. The pellets (P) and supernatants (S) were then assayed for
GSK3 activity using the GS-1 peptide. The data show the average
of duplicate assays for a single experiment and are plotted relative
to the activity of control incubations in which Sepharose and Se-
pharose-FRATtide were omitted and stored on ice. Similar results
were obtained in three (B) or two (C) further analyses.
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growth factor-1 to activate glycogen synthase in these cells
(data not shown). FRATtide also had little e¡ect on GSK3
activity towards a synthetic peptide corresponding to the se-
quence surrounding the phosphorylation site on eIF2B (Fig.
5B).
In contrast to the GS-1 peptide, glycogen synthase and the
eIF2B peptide, the GSK3-catalysed phosphorylation of Tau
was completely inhibited by FRATtide (closed circles in Fig.
6). Axin was not present in these assays, implying that the
inhibition of Tau phosphorylation by FRATtide was not oc-
curring by the mechanism invoked for inhibition of L-catenin
phosphorylation (i.e. displacement of Axin from GSK3). A
second/alternative mechanism of inhibition was also suggested
by the observation that L-catenin phosphorylation is blocked
by slightly lower concentrations of FRATtide than Axin
phosphorylation and that FRATtide reduced the level of L-
catenin phosphorylation below that observed in the absence of
Axin (Fig. 4B). This should not be the case if dissociation of
Axin from GSK3 was the sole mechanism by which FRAT-
tide inhibits the phosphorylation of Axin and L-catenin.
GSK3 preferentially phosphorylates proteins and peptides
at serine or threonine residues that are followed by another
phosphoserine, frequently located four residues C-terminal to
the GSK3 site [26,27]. Indeed, glycogen synthase [27], the
GS-1 peptide [28] and the eIF2B-derived peptide [29] are
not phosphorylated by GSK3, unless such a ‘priming’ phos-
phorylation is present (see Section 2). The proteins whose
phosphorylation by GSK3 was una¡ected by FRATtide
(Fig. 5) all contained a ‘priming phosphorylation’ and were
phosphorylated at high rates in vitro, while those proteins
whose phosphorylation was prevented by FRATtide (Axin,
L-catenin and Tau) were expressed in E. coli, did not possess
a priming phosphorylation and were phosphorylated by
GSK3 in vitro at rates 100^1000-fold slower than the peptide
GS-1. We therefore wondered whether resistance to inhibition
by FRATtide was conferred by a priming phosphorylation.
Indeed, prior phosphorylation of Tau with p42 MAP kinase,
which phosphorylates Ser-235 (and other residues) and allows
GSK3 to phosphorylate Thr-231 [30], increased the rate of
Tau phosphorylation about 50-fold and abolished inhibition
by FRATtide (Fig. 6).
There is currently no evidence to support the idea that a
‘priming’ phosphorylation is a prerequisite for the GSK3-cat-
alysed phosphorylation of Axin or L-catenin in vivo. High
levels of Axin and L-catenin phosphorylation may be attained
in vivo because their rates of dephosphorylation in the GSK3-
Axin-L-catenin ternary complex are very slow. This is consis-
tent with the observation that maximal dephosphorylation of
Axin and accumulation of L-catenin only occurs after stimu-
lation with Wnt3A for several hours [12]. In contrast, the
insulin-induced dephosphorylation of glycogen synthase oc-
Fig. 4. FRATtide prevents the GSK3-catalysed phosphorylation of
Axin and L-catenin. The phosphorylation of Axin[281-500] (92 nM)
(A) and L-catenin (430 nM) (B) by His-tagged human GSK3L
(1.0 U/ml, 94 nM) was assayed in the presence of the indicated con-
centrations of FRATtide. GSK3 was incubated with FRATtide for
10 min before the addition of substrate and Mg[Q-32P]ATP. The re-
actions were terminated after 20 min at 30‡C by addition of 0.2 vol-
umes of 8% (w/v) SDS and then incubated with nickel-nitrilotriace-
tate-agarose to remove the GSK3L. The supernatant was removed
and electrophoresed on an 8% SDS-polyacrylamide gel, followed by
autoradiography.
Fig. 5. Lack of an e¡ect of FRATtide on GSK3 kinase activity to-
wards three substrates. The phosphorylation of GS-1 (A), the
eIF2B-derived peptide (B) and glycogen synthase (C) by GSK3
(0.1 U/ml) was assayed in the presence of the indicated concentra-
tions of FRATtide. GSK3 was incubated with FRATtide for 10 min
before the addition of substrate and Mg[Q-32P]ATP. In C, the reac-
tion was terminated by addition of 0.2 volumes of 10% (w/v) SDS
and, after electrophoresis on a 12% SDS-polyacrylamide gel, the gel
was autoradiographed.
Fig. 3. FRATtide prevents binding of GSK3 to Axin. GSK3K or
GSK3L (duplicate samples of each) were pre-incubated with or
without 0.2 mM FRATtide, added to GST-Axin[281-500] that had
been pre-coupled to glutathione-Sepharose and incubated for 60 min.
GSK3 bound to the pelleted beads (P) and unbound material re-
maining in the supernatant (S) were analysed by immunoblotting.
The control lane (C) shows a GSK3 standard.
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curs with a half-time of less than 5 min and is maximal after
15 min [31].
The peptide GS-1 did not prevent FRATtide from forming
a complex with GSK3 (data not shown), indicating that the
failure of FRATtide to inhibit phosphorylation of this sub-
strate was not explained by the inability of FRATtide to bind
to GSK3 in the presence of this or other ‘primed’ substrates.
However, FRATtide might prevent ‘unprimed’ substrates
from interacting with GSK3 and ‘primed’ substrates might
be resistant to inhibition by FRATtide because they interact
with GSK3 much more strongly. Whatever the explanation,
the inability of FRATtide to prevent the GSK3-catalysed
phosphorylation of several of its physiological substrates is
likely to be signi¢cant, allowing many of the essential func-
tions of GSK3 to proceed normally despite the suppression of
L-catenin and Axin phosphorylation.
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Fig. 6. The ability of FRATtide to prevent the GSK3-catalysed
phosphorylation of Tau depends on phosphorylation at a ‘priming’
site. Tau that had been pre-phosphorylated with p42 MAP kinase
(open circles) or not pre-phosphorylated (closed circles) was incu-
bated for 10 min using GSK3 (0.1 U/ml) and Mg[Q-32P]ATP in the
presence of the indicated concentrations of FRATtide. Results are
plotted relative to the rate of phosphorylation in the absence of
FRATtide. No phosphorylation of Tau occurred in the absence of
added GSK3.
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